| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8486941 | GLAXOSMITHKLINE | Phenyl amino pyrimidine compounds and uses thereof |
Jan, 2030
(5 years from now) | |
| USRE48285 | GLAXOSMITHKLINE | N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide |
Jun, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9809559 | GLAXOSMITHKLINE | (N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide |
Jun, 2035
(11 years from now) | |
Ojjaara is owned by Glaxosmithkline.
Ojjaara contains Momelotinib Dihydrochloride.
Ojjaara has a total of 3 drug patents out of which 0 drug patents have expired.
Ojjaara was authorised for market use on 15 September, 2023.
Ojjaara is available in tablet;oral dosage forms.
Ojjaara can be used as for the treatment of intermediate or high-risk myelofibrosis.
Drug patent challenges can be filed against Ojjaara from 16 September, 2027.
The generics of Ojjaara are possible to be released after 11 June, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-441) | Sep 15, 2030 |
| New Chemical Entity Exclusivity(NCE) | Sep 15, 2028 |
Drugs and Companies using MOMELOTINIB DIHYDROCHLORIDE ingredient
NCE-1 date: 16 September, 2027
Market Authorisation Date: 15 September, 2023
Treatment: For the treatment of intermediate or high-risk myelofibrosis
Dosage: TABLET;ORAL
OJJAARA family patents
